175 related articles for article (PubMed ID: 24861993)
1. Desensitization protocol for rituximab-induced serum sickness.
Fajt ML; Petrov AA
Curr Drug Saf; 2014; 9(3):240-2. PubMed ID: 24861993
[TBL] [Abstract][Full Text] [Related]
2. [Repeated rituximab-induced serum sickness with anaphylaxis].
Isoda A; Ishikawa T; Sato N; Miyazawa Y; Matsumoto M; Sawamura M
Rinsho Ketsueki; 2016 Jun; 57(6):771-3. PubMed ID: 27384859
[TBL] [Abstract][Full Text] [Related]
3. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
Wong JT; Long A
J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
Le Guenno G; Ruivard M; Charra L; Philippe P
Intern Med J; 2011 Feb; 41(2):202-5. PubMed ID: 22747556
[TBL] [Abstract][Full Text] [Related]
6. Serum sickness following treatment with rituximab.
Todd DJ; Helfgott SM
J Rheumatol; 2007 Feb; 34(2):430-3. PubMed ID: 17295433
[TBL] [Abstract][Full Text] [Related]
7. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
Hellerstedt B; Ahmed A
Ann Oncol; 2003 Dec; 14(12):1792. PubMed ID: 14630688
[No Abstract] [Full Text] [Related]
8. Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.
Blase JR; Frame D; Michniacki TF; Walkovich K
Front Immunol; 2022; 13():863177. PubMed ID: 35514985
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
Nakamura M; Kanda S; Yoshioka Y; Takahashi C; Owada K; Kajiho Y; Harita Y; Oka A
CEN Case Rep; 2020 May; 9(2):173-176. PubMed ID: 31970629
[TBL] [Abstract][Full Text] [Related]
10. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-induced remission of a gastric MALT lymphoma.
Datta YH; Kampalath B; Binion DG
Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Hypersensitivity: From Clinical Presentation to Management.
Fouda GE; Bavbek S
Front Pharmacol; 2020; 11():572863. PubMed ID: 33013416
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
14. Rituximab desensitization in three patients with severe rituximab allergy.
Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-induced serum sickness in multiple sclerosis patients.
Wolf AB; Ryerson LZ; Pandey K; McGettigan BM; Vollmer T; Corboy JR; Alvarez E
Mult Scler Relat Disord; 2019 Nov; 36():101402. PubMed ID: 31542710
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma.
Stalika E; Kanellis G; Papalexandri A; Iskas M; Vrakidou E; Demonakou M; Anagnostopoulos A; Stamatopoulos K; Papadaki T
Leuk Lymphoma; 2014 Mar; 55(3):702-5. PubMed ID: 23725385
[No Abstract] [Full Text] [Related]
18. Desensitization to rituximab in a multidisciplinary setting.
Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
[TBL] [Abstract][Full Text] [Related]
19. Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma.
Kahara T; Iwaki N; Kaya H; Kurokawa T; Yoshida T; Ishikura K; Usuda R
Endocr J; 2011; 58(1):7-12. PubMed ID: 21068513
[TBL] [Abstract][Full Text] [Related]
20. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan.
DeMonaco NA; Jacobs SA
Clin Nucl Med; 2007 Dec; 32(12):933-4. PubMed ID: 18030044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
